Back to top
more

Capricor Therapeutics (CAPR)

(Real Time Quote from BATS)

$5.86 USD

5.86
132,620

-0.24 (-3.93%)

Updated May 29, 2024 11:22 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 249)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for CAPR

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Capricor Therapeutics, Inc. [CAPR]

Reports for Purchase

Showing records 21 - 40 ( 82 total )

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 21

04/02/2020

Company Report

Pages: 8

KOL Call Puts Exosomes in the Spotlight for Anti- COVID-19 Vaccine Development and Beyond

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 22

03/19/2020

Company Report

Pages: 6

2019 Results; All Eyes on CAP-1002 Topline Data in 2Q20 While Leveraging Exosomes Against COVID-19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 23

01/21/2020

Company Report

Pages: 7

2020 Is Crunch Time; Upcoming 12-Month HOPE-2 Data Could Be Company Defining; Target Adjusted to $9

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 24

10/11/2019

Company Report

Pages: 8

Added Early Data Point to Fruitful Upcoming FDA Discussion for DMD Path Forward Under RMAT

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 25

08/08/2019

Company Report

Pages: 6

2Q19 Results; CAP-1002 Solidifies the Ground for Potential Pivotal Design; Target Reverse-Split Adjusted to $19.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 26

07/15/2019

Company Report

Pages: 10

Happy Monday; Interim HOPE-2 Data Impress; Target Increased to $12.40

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 27

05/14/2019

Company Report

Pages: 7

1Q19 Results; All Eyes Remain on the 3Q19 HOPE-2 Interim Analysis

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 28

05/01/2019

Company Report

Pages: 7

Laser-Like Focus on HOPE-2 Interim Analysis Set for 3Q19

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 29

12/31/2018

Company Report

Pages: 6

Expecting Only a Brief Perception Knock That Should Be Back to Normal in a Couple of Months; Target Reduced to $3.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 30

11/20/2018

Company Report

Pages: 6

Leveraging RMAT Status for HOPE-2; 3Q18 Results

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 31

09/07/2018

Company Report

Pages: 4

We are dropping coverage of CAPR shares to reallocate our research resources

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 32

08/10/2018

Company Report

Pages: 6

2Q18 Results; HOPE-2 Gaining Steam as Truly Unique DMD Opportunity; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 33

05/11/2018

Company Report

Pages: 6

1Q18 Results; Capricor Has Gone Officially Pivotal; Expect Visibility Around Trial to Increase Significantly

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 34

03/29/2018

Company Report

Pages: 8

Pivotal HOPE-2 Should Start Imminently; RMAT Designation, and 2017 Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 35

01/26/2018

Company Report

Pages: 7

All Eyes to HOPE-2 Start and Execution; Reiterate Buy and Target Increased to $8.60

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 36

09/15/2017

Company Report

Pages: 11

Looking to 4Q17 DMD Drivers Now That Cardio Dust Has Settled; Target Increased to $6.50

Provider: H.C. Wainwright & Co., Inc.

Analyst: PANTGINIS J

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 37

08/14/2017

Company Report

Pages: 6

2Q17 Results; Anticipating Solidified Investment Case in 4Q17

Provider: H.C. Wainwright & Co., Inc.

Price: 25.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 38

07/18/2017

Daily Note

Pages: 5

FDA Is Engaged in a Big Way; We''re Happy; Potential Priority Review Voucher in the Future?

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 39

07/18/2017

Daily Note

Pages: 5

FDA Is Engaged in a Big Way; We''re Happy; Potential Priority Review Voucher in the Future?

Provider: H.C. Wainwright & Co., Inc.

Price: 10.00

Research Provided by a Third Party

Company: Capricor Therapeutics, Inc.

Industry: Medical - Products

Record: 40

07/10/2017

Company Report

Pages: 5

Janssen Opts-Out, But There Is Always HOPE; Eyes to FDA Now for DMD

Provider: Rodman & Renshaw, Co.

Price: 10.00

Research Provided by a Third Party